✦ LIBER ✦

Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial: Ann Intern Med 1994; 121/1; 1–5

✍ Scribed by RV McCloskey; RC Straube; C Sanders; SM Smith; CR Smith

Book ID: 103661412
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 249 KB
Volume: 30
Category: Article
ISSN: 0300-9572
DOI: 10.1016/0300-9572(95)94129-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon-α is effective in the treatme

Interferon-α is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia: A prospective, placebo-controlled, double-blind trial: Marroni M, Gresele P, Landonio G, et al. Ann Intern Med 121:423–429, 1994

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Treatment of rheumatoid arthritis with a

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four–week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Stanley Cohen; Eric Hurd; John Cush; Michael Schiff; Michael E. Weinblatt; Larry 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views